Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Beats Expectations By $0.04 EPS

Key Points

• Denali reported EPS of ($0.69), beating estimates by $0.04 and improving from ($0.78) a year ago, but its shares fell 3.4% to $19.71 on the news.
• Analysts have a "Moderate Buy" consensus with an average price target of $35, and the majority of ratings are Buy/Strong Buy.
• Denali is a clinical‑stage biotech focused on neurodegenerative therapies using a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform, with lead programs including an oral LRRK2 inhibitor for Parkinson's and an anti‑TREM2 antibody for Alzheimer's.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.04, FiscalAI reports. During the same quarter last year, the firm posted ($0.78) earnings per share.

Denali Therapeutics Trading Down 3.4%

Shares of NASDAQ:DNLI traded down $0.70 during trading on Thursday, hitting $19.71. 1,228,501 shares of the company's stock were exchanged, compared to its average volume of 1,581,428. Denali Therapeutics has a 1-year low of $12.58 and a 1-year high of $23.77. The firm has a 50-day moving average price of $20.19 and a two-hundred day moving average price of $18.86. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The firm has a market cap of $3.13 billion, a P/E ratio of -6.64 and a beta of 0.99.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DNLI. UBS Group began coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They issued a "buy" rating for the company. Wolfe Research began coverage on shares of Denali Therapeutics in a research report on Monday, February 23rd. They issued a "peer perform" rating for the company. Jefferies Financial Group restated a "buy" rating and issued a $40.00 price objective on shares of Denali Therapeutics in a research report on Monday, March 2nd. Wall Street Zen cut shares of Denali Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, April 25th. Finally, Leerink Partners lowered their price objective on shares of Denali Therapeutics from $40.00 to $35.00 and set an "outperform" rating for the company in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $35.00.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors have recently modified their holdings of the business. Headlands Technologies LLC acquired a new stake in shares of Denali Therapeutics during the 2nd quarter worth approximately $26,000. Johnson Financial Group Inc. acquired a new stake in shares of Denali Therapeutics during the 3rd quarter worth approximately $29,000. State of Wyoming acquired a new stake in shares of Denali Therapeutics during the 2nd quarter worth approximately $29,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $57,000. Finally, Quarry LP bought a new position in Denali Therapeutics during the 3rd quarter worth approximately $64,000. Institutional investors and hedge funds own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.